Peier Biomedical - Chuang's 115th Annual General Meeting Approves Removal of Director's Non-Competition Restriction

1. Date of shareholders' meeting resolution: 115/06/18 2. Name and title of director permitted to engage in competitive activities: Lin Cheng-Long / Chairman 3. Nature of permitted competitive activities: Companies with business scope identical or similar to that of the company 4. Duration of permitted competitive activities: During the period serving as director of the company 5. Resolution outcome (voting results per Article 209 of the Company Act): Passed by more than two-thirds of the voting rights of attending shareholders, with shareholders representing over half of the issued shares in attendance 6. Director's name and title if the permitted competitive activity involves a business in mainland China (enter 'Not applicable' if not): Lin Cheng-Long / Chairman 7. Name and position held in the mainland China-based enterprise: Pei (Yue Tai) (Shanghai) Medical Technology Co., Ltd. / Chairman 8. Address of the mainland China-based enterprise: Room 319, 3rd Floor, Building 4, No. 889 Bibo Road, China (Shanghai) Pilot Free Trade Zone 9. Business scope of the mainland China-based enterprise: General activities: Technical services, technical development, technical consulting, technical exchange, technology transfer, and technology promotion; import and export of goods; import and export of technology. (Except for projects requiring legal approval, all business activities are conducted independently based on business licenses.) Featured activities: Medical research or experimental development (excluding human stem cells, gene diagnosis and therapy technology development and application); engineering and technical research and experimental development (excluding human stem cells, gene diagnosis and therapy technology development and application, and China's rare and unique precious species); sales of specialty chemical products (excluding hazardous chemicals) 10. Impact on the company's financial and operational status: None 11. If the director has invested in the mainland China-based enterprise, the investment amount and ownership ratio: Not applicable 12. Other matters to be disclosed: None